<DOC>
	<DOCNO>NCT02390596</DOCNO>
	<brief_summary>The study design assess efficacy safety anakinra , interleukin 1 receptor antagonist , patient Kawasaki disease fail respond standard treatment : e.g . one infusion 2g/kg intravenous immunoglobulin .</brief_summary>
	<brief_title>Anakinra Kawasaki Disease</brief_title>
	<detailed_description>Kawasaki disease ( KD ) , frequent vasculitis child 5 year , main cause acquire cardiomyopathy adulthood . The prognosis KD influence early recognition treatment intravenous immunoglobulin ( IVIG ) , represent standard care decrease significantly risk coronary aneurysm . Despite first infusion IVIG , 20 % KD patient remain febrile high risk coronary vasculitis . To date agreement effective second line treatment . On basis autoinflammatory pattern KD , hypothesize anti IL-1 blocking agent could bring rapid sustained effect systemic coronary inflammation patient KD . Aim study - To assess efficacy anakinra ( IL-1R1receptor antagonist ) patient KD fail respond one infusion IVIg ( standard treatment ) . - To assess efficacy anakinra disease activity - To assess efficacy anakinra coronary lesion ( eg : dilatation aneurysm - To assess safety tolerability anakinra Patients methods A Proof concept ( quasi experimental , non randomize cohort ) study . This 2-year open-label , prospective multicenter trial Anakinra patient acute KD fail respond first infusion IVIG within 48h . Patients eligible enter study persistence ( recrudescence fever ) within 48 hour infusion IVIg , give informed consent enter study . After appropriate screening , study treatment initiate J7 J14 day illness expect full clinical effect . The primary endpoint absence fever 48 h treatment ( assess J3 study treatment , visit 3 , third injection anakinra ) . If patient remains febrile ( fever &gt; 38°C ) , receive double dose anakinra ( 4mg/kg ) day 3 instead 2mg/kg . Treatment continue achieve complete response define outcome measurement section , maximum 15 day . Expected result expect public health benefit Anakinra treatment expect reduce early long term mortality patient KD , rapid sustain effect vascular inflammation . The safety anakinra expect good , drug short half-life , allow rapid withdrawal case serious adverse event . The use anakinra , associate risk contamination infectious agent , remain even minimal , possibility use IVIG</detailed_description>
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Patients , male female , age ≥ 8 month ( 10kg ) life , KD accord American Heart Association definition complete incomplete KD . fever ≥ 5 day ≥ 4 5 main clinical sign : modification extremity , polymorphic exanthema , bilateral bulbar exudative conjunctivitis , erythema lip oral cavity , cervical lymph node usually unilateral &gt; 1.5 cm diameter . In presence le 4 clinical criterion 5 day fever , diagnosis disease KD propose case coronary abnormality ( least one dilated coronary artery internal diameter ≥ 2,5 SD mean normalize body surface area ( Z score ) determine echocardiography . For indicative purpose , case incomplete KD , biological supportive criterion incomplete KD help ensure diagnosis : leucocytosis , elevate CRP , elevate ESR , anaemia , hyponatremia , elevate ASAT , ALAT gGT , hyperlipidaemia . Patients fail respond standard therapy KD : , e.g . Persistence recrudescence fever ≥ 38°C , 48 hour infusion 2g/kg IV Ig , Weight ≥10Kg Patient , parent legal guardian 's write informed consent require Patient health insurance Patient agree effective contraception duration participation research Preterm neonates , pregnancy Patients suspect another diagnosis Patients overt concomitant bacterial infection Patients previously treat another biotherapy Patients type immunodeficiency cancer Patients increase risk TB infection Recent tuberculosis infection active TB Close contact patient TB Patients recently arrive less 3 month country high prevalence TB A chest radiograph suggestive TB Patients end stage renal disease : NKF stag ≥4 ; eGFR≤29mL/min/1.73 m2 diabetes mellitus neutropenia &lt; 1500/mm3 liver failure Hypersensitivity active substance excipients ( citric acid anhydrous ; sodium chloride disodium edetate dehydrate polysorbate 80 ; sodium hydroxide ; water injection ) Patient already include biomedical research observational ( e.g . ; cohort , registry )</criteria>
	<gender>All</gender>
	<minimum_age>8 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Kawasaki disease</keyword>
	<keyword>anti Interleukin 1 treatment</keyword>
	<keyword>anakinra</keyword>
	<keyword>resistance IVIg</keyword>
	<keyword>coronary aneurysm</keyword>
	<keyword>phase II trial</keyword>
</DOC>